- Home
- EXAS vs CORT Comparison
EXAS vs CORT Comparison
Compare EXAS & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- CORT
- Stock Information
- Founded
- EXAS 1995
- CORT 1998
- Country
- EXAS United States
- CORT United States
- Employees
- EXAS N/A
- CORT N/A
- Industry
- EXAS Medical Specialities
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- EXAS Health Care
- CORT Health Care
- Exchange
- EXAS Nasdaq
- CORT Nasdaq
- Market Cap
- EXAS 10.6B
- CORT 8.8B
- IPO Year
- EXAS N/A
- CORT N/A
- Fundamental
- Price
- EXAS $57.01
- CORT $90.12
- Analyst Decision
- EXAS Strong Buy
- CORT Strong Buy
- Analyst Count
- EXAS 21
- CORT 4
- Target Price
- EXAS $67.86
- CORT $139.00
- AVG Volume (30 Days)
- EXAS 2.3M
- CORT 911.1K
- Earning Date
- EXAS 11-04-2025
- CORT 10-29-2025
- Dividend Yield
- EXAS N/A
- CORT N/A
- EPS Growth
- EXAS N/A
- CORT N/A
- EPS
- EXAS N/A
- CORT 1.11
- Revenue
- EXAS $2,939,949,000.00
- CORT $716,080,000.00
- Revenue This Year
- EXAS $16.68
- CORT $30.77
- Revenue Next Year
- EXAS $12.08
- CORT $37.75
- P/E Ratio
- EXAS N/A
- CORT $79.09
- Revenue Growth
- EXAS 12.55
- CORT 25.71
- 52 Week Low
- EXAS $38.81
- CORT $42.01
- 52 Week High
- EXAS $72.83
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- EXAS 68.53
- CORT 78.03
- Support Level
- EXAS $52.85
- CORT $82.65
- Resistance Level
- EXAS $54.74
- CORT $85.91
- Average True Range (ATR)
- EXAS 1.40
- CORT 2.86
- MACD
- EXAS 0.17
- CORT 0.81
- Stochastic Oscillator
- EXAS 93.39
- CORT 98.90
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.